Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,858,912 papers from all fields of science
Search
Sign In
Create Free Account
HER2-targeted Liposomal Doxorubicin Hydrochloride MM-302
Known as:
MM-302
An antibody-targeted lipidic nano-carrier containing the antineoplastic anthracycline antibiotic doxorubicin encapsulated within liposomes, and…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract P4-21-40: In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors
E. Geretti
,
C. Espelin
,
+17 authors
T. Wickham
2017
Corpus ID: 164563492
2017
2017
Abstract P3-06-05: Receptor-mediated binding of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 increases liposome binding, nuclear doxorubicin, DNA damage and efficacy relative to…
C. Espelin
,
E. Geretti
,
+6 authors
T. Wickham
2017
Corpus ID: 78221089
2017
2017
Pet Imaging Of Early Therapeutic Response In Solid Tumors
S. Blocker
2017
Corpus ID: 79706394
PET IMAGING OF EARLY THERAPEUTIC RESPONSE IN SOLID TUMORS by STEPHANIE J. BLOCKER December 2017 Advisor: Dr. Anthony F. Shields…
Expand
2016
2016
Abstract OT3-01-01: HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive…
K. Miller
,
J. Cortes
,
+8 authors
D. Yardley
2016
Corpus ID: 76879292
Background: Although HER2-targeted therapies such as pertuzumab and T-DM1 have improved patient outcomes, treatment resistance…
Expand
2015
2015
Abstract 4134: MM-302 is more effective than PEGylated liposomal doxorubicin (PLD) at reducing pulmonary metastatic burden in breast cancer models expressing intermediate levels of HER2
N. Dumont
,
E. Geretti
,
+5 authors
T. Wickham
2015
Corpus ID: 73826583
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Introduction: Despite improvements in treatment…
Expand
2015
2015
MM-302 Shows Promise in Heavily Pretreated HER2-Positive Breast Cancer
L. Lawrence
2015
Corpus ID: 164779251
MM-302 showed encouraging efficacy results and a manageable safety profile in heavily pretreated HER2-positive metastatic breast…
Expand
2013
2013
Abstract 3271: Tumor priming with cyclophosphamide increases delivery and activity of Her2-targeted liposomal doxorubicin (MM-302) in preclinical models of breast cancer.
E. Geretti
,
S. Leonard
,
Daniel F. Gaddy
,
N. Dumont
,
T. Wickham
,
B. Hendriks
2013
Corpus ID: 76493448
2012
2012
Abstract P4-02-05: A novel 64Cu-liposomal PET agent (MM-DX-929) predicts response to liposomal chemotherapeutics in preclinical breast cancer models
Helen Lee
,
Jinzi Zheng
,
+7 authors
T. Wickham
2012
Corpus ID: 74856195
Background: Liposomal anthracyclines (such as pegylated liposomal doxorubicin (PLD) or HER2-targeted liposomal doxorubicin (MM…
Expand
2011
2011
Abstract 3637: MM-302, a HER2-targeted liposomal doxorubicin, shows binding/uptake and efficacy in HER2 2+ cells and xenograft models
S. Klinz
,
Isabelle Eckelhofer
,
+6 authors
T. Wickham
2011
Corpus ID: 76543688
Introduction: MM-302 is an ErbB2/HER2-targeted liposomal doxorubicin formulation designed to target doxorubicin to HER2…
Expand
2010
2010
Abstract P3-14-09: Preclinical Safety and Activity of MM-302, a HER2-Targeted Liposomal Doxorubicin Designed To Have an Improved Safety and Efficacy Profile over Approved Anthracyclines
T. Wickham
,
Joe Reynolds
,
+14 authors
U. Nielsen
2010
Corpus ID: 72743563
Background: Anthracyclines have been an effective backbone of breast cancer therapies for decades. However, cardiotoxicity issues…
Expand